Injection demonstrated significantly greater improvement on the primary endpoint of mean visual acuity letter score change at one year [Eylea +13 letters; bevacizumab (Avastin) +10; ranibizumab ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections compared to Eylea. Read more here.
The 64-week trial is comparing Novartis’ drug with the current formulation of Eylea, while last year the FDA approved a 12-weekly injection ... s VEGF inhibitor Avastin (bevacizumab), which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback